Ipca Laboratories - Public Comps and Valuation Multiples

Ipca Laboratories Overview

About Ipca Laboratories

Ipca Laboratories Ltd is a pharmaceutical company. The company's principal activity is the Development, Manufacturing, and Marketing of Pharmaceuticals Products. The company's API products include Atenolol (anti-hypertensive), Chloroquine Phosphate (anti-malarial), Chlorthalidone (diuretic), Furosemide (diuretic), Hydroxychloroquine Sulphate (DMARD), Losartan. The company has only one reportable primary business segment, pharmaceuticals.

Founded

1949

HQ

Employees

18.0K+

Website

ipca.com

Sectors

Drug Development & Therapeutics
BioTech

Financials

LTM Revenue $1.1B

LTM EBITDA $208M

EV

$3.7B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Ipca Laboratories Financials

As of September 2025, Ipca Laboratories reported last 12-month revenue of $1.1B and EBITDA of $208M.

In the same period, Ipca Laboratories generated $726M in LTM gross profit and $119M in net income.

See Ipca Laboratories valuation multiples based on analyst estimates

Ipca Laboratories P&L

In the most recent fiscal year, Ipca Laboratories reported revenue of $999M and EBITDA of $182M.

Ipca Laboratories expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Ipca Laboratories valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$1.1B	XXX	$999M	XXX	XXX	XXX
Gross Profit	$726M	XXX	$668M	XXX	XXX	XXX
Gross Margin	68%	XXX	67%	XXX	XXX	XXX
EBITDA	$208M	XXX	$182M	XXX	XXX	XXX
EBITDA Margin	20%	XXX	18%	XXX	XXX	XXX
EBIT	$165M	XXX	$153M	XXX	XXX	XXX
EBIT Margin	16%	XXX	15%	XXX	XXX	XXX
Net Profit	$119M	XXX	$83.2M	XXX	XXX	XXX
Net Margin	11%	XXX	8%	XXX	XXX	XXX
Net Debt	XXX	XXX	$128M	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Ipca Laboratories including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $1.1B. EBITDA for the last twelve months was $208M. In the most recent fiscal year, Ipca Laboratories achieved $999M in revenue and $182M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$1.1B	Analyst estimates available to subscribers	$999M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$726M	Analyst estimates available to subscribers	$668M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	68.1% gross margin	Analyst estimates available to subscribers	66.9% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$208M	Analyst estimates available to subscribers	$182M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	19.5% EBITDA margin	Analyst estimates available to subscribers	18.2% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$165M	Analyst estimates available to subscribers	$153M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	15.5% EBIT margin	Analyst estimates available to subscribers	15.3% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$119M	Analyst estimates available to subscribers	$83.2M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	11.2% net profit margin	Analyst estimates available to subscribers	8.3% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	$128M	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Ipca Laboratories

This financial data table provides comprehensive performance metrics for Ipca Laboratories, a company based in India. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Ipca Laboratories generated $1.1B in revenue over the last twelve months.
The company achieved $208M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $726M.
Net income over the last twelve months reached $119M.

Fiscal Year Performance

In the most recent fiscal year, Ipca Laboratories reported $999M in total revenue.
Fiscal year EBITDA was $182M.
The company maintained a gross profit margin of 66.9% in the most recent fiscal year.
EBITDA margin for the fiscal year was 18.2%.
Net profit margin reached 8.3% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Ipca Laboratories. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Ipca Laboratories Stock Performance

Ipca Laboratories has current market cap of INR 327B (or $3.7B), and EV of INR 329B (or $3.7B).

Market Cap Evolution

Ipca Laboratories Stock Data

As of October 17, 2025, Ipca Laboratories's stock price is INR 1288 (or $15).

See Ipca Laboratories trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$3.7B	$3.7B	XXX	XXX	XXX	XXX	$0.47

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Ipca Laboratories Valuation Multiples

Ipca Laboratories's trades at 3.9x EV/Revenue multiple, and 21.3x EV/EBITDA.

See valuation multiples for Ipca Laboratories and 15K+ public comps

Ipca Laboratories Financial Valuation Multiples

As of October 17, 2025, Ipca Laboratories has market cap of $3.7B and EV of $3.7B.

Equity research analysts estimate Ipca Laboratories's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Ipca Laboratories has a P/E ratio of 31.0x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$3.7B	XXX	$3.7B	XXX	XXX	XXX
EV (current)	$3.7B	XXX	$3.7B	XXX	XXX	XXX
EV/Revenue	3.5x	XXX	3.9x	XXX	XXX	XXX
EV/EBITDA	17.8x	XXX	21.3x	XXX	XXX	XXX
EV/EBIT	22.5x	XXX	26.3x	XXX	XXX	XXX
EV/Gross Profit	5.1x	XXX	n/a	XXX	XXX	XXX
P/E	31.0x	XXX	47.3x	XXX	XXX	XXX
EV/FCF	40.0x	XXX	60.7x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Ipca Laboratories Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Ipca Laboratories Margins & Growth Rates

Ipca Laboratories's last 12 month revenue growth is 11%

Ipca Laboratories's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $29K for the same period.

Ipca Laboratories's rule of 40 is 29% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Ipca Laboratories's rule of X is 47% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Ipca Laboratories and other 15K+ public comps

Ipca Laboratories Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	11%	XXX	12%	XXX	XXX	XXX
EBITDA Margin	20%	XXX	18%	XXX	XXX	XXX
EBITDA Growth	17%	XXX	20%	XXX	XXX	XXX
Rule of 40	29%	XXX	29%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	47%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.1M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$29K	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	10%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	1%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	52%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial